Effects of Weight-Loss Medications on Cardiometabolic Risk Profiles: A Systematic Review and Network Meta-analysis.

Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, Berry JD, Camilleri M, Singh S

Gastroenterology3 Jan 2018Cited by 67 (Europe PMC)

PMID29305933PMCIDPMC5880739DOI10.1053/j.gastro.2017.12.024PepBankPUB-29305933

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

5 results from studies that gave the peptide. 5 results from people.

01HumanSystematic reviewEfficacy outcome
In a network meta-analysis of weight-loss trials in obese adults, liraglutide was associated with a substantial decrease in fasting blood glucose.
In plain wordsIn obese adults, trials combined in a network meta-analysis linked liraglutide to a substantial drop in fasting blood glucose.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose
Study
n: not reported in source
Comparator
Placebo or other active agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 year or moreAs given in this study (human).
Source sentences
Summary
Liraglutide use was associated with a substantial decrease in FBG, hemoglobin A1c, and WC, and a minimal effect on BP and cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
Report a problemFND-2930593301
02HumanSystematic reviewEfficacy outcome
In a network meta-analysis of weight-loss trials in obese adults, liraglutide was associated with a substantial decrease in hemoglobin A1c.
In plain wordsIn obese adults, trials combined in a network meta-analysis linked liraglutide to a substantial drop in HbA1c.
Peptide
Liraglutide
Outcome
DecreaseHemoglobin A1c
Study
n: not reported in source
Comparator
Placebo or other active agents
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 1 year or moreAs given in this study (human).
Source sentences
Summary
Liraglutide use was associated with a substantial decrease in FBG, hemoglobin A1c, and WC, and a minimal effect on BP and cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
Report a problemFND-2930593302
03HumanSystematic reviewEfficacy outcome
In a network meta-analysis of weight-loss trials in obese adults, liraglutide was associated with a substantial decrease in waist circumference.
In plain wordsIn obese adults, trials combined in a network meta-analysis linked liraglutide to a substantial drop in waist size.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference
Study
n: not reported in source
Comparator
Placebo or other active agents
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 1 year or moreAs given in this study (human).
Source sentences
Summary
Liraglutide use was associated with a substantial decrease in FBG, hemoglobin A1c, and WC, and a minimal effect on BP and cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
Report a problemFND-2930593303
04HumanSystematic reviewEfficacy outcome
In a network meta-analysis of weight-loss trials in obese adults, liraglutide had a minimal effect on blood pressure.
In plain wordsIn obese adults, trials combined in a network meta-analysis linked liraglutide to a minimal change in blood pressure.
Peptide
Liraglutide
Outcome
No significant changeBlood pressure
Study
n: not reported in source
Comparator
Placebo or other active agents
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 1 year or moreAs given in this study (human).
Source sentences
Summary
Liraglutide use was associated with a substantial decrease in FBG, hemoglobin A1c, and WC, and a minimal effect on BP and cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
Report a problemFND-2930593304
05HumanSystematic reviewEfficacy outcome
In a network meta-analysis of weight-loss trials in obese adults, liraglutide had a minimal effect on the cholesterol profile.
In plain wordsIn obese adults, trials combined in a network meta-analysis linked liraglutide to a minimal change in cholesterol.
Peptide
Liraglutide
Outcome
No significant changeCholesterol profile
Study
n: not reported in source
Comparator
Placebo or other active agents
Outcome group
Lipids · Cardiovascular
Studied dose
Dose not stated · 1 year or moreAs given in this study (human).
Source sentences
Summary
Liraglutide use was associated with a substantial decrease in FBG, hemoglobin A1c, and WC, and a minimal effect on BP and cholesterol.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
Report a problemFND-2930593305

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss medications (including liraglutide) were associated with a modest decrease in fasting blood glucose versus placebo.
In plain wordsIn obese adults, weight-loss drugs as a group, including liraglutide, were linked to a modest drop in fasting blood glucose compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose, pooled weight-loss drugs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
we associated weight-loss medications with a modest decrease in FBG (weighted mean difference, 4.0 mg/dL; 95% confidence interval, -4.4 to -3.6 mg/dL)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2930593306
07HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss medications (including liraglutide) were associated with a modest decrease in waist circumference versus placebo.
In plain wordsIn obese adults, weight-loss drugs as a group, including liraglutide, were linked to a modest drop in waist size compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseWaist circumference, pooled weight-loss drugs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
we associated weight-loss medications with a modest decrease in FBG (weighted mean difference, 4.0 mg/dL; 95% confidence interval, -4.4 to -3.6 mg/dL) and WC (weighted mean difference, reduction of 3.3 cm; 95% confidence interval, -3.5 to -3.1 cm)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2930593307
08HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss medications (including liraglutide) produced no clinically meaningful change in systolic or diastolic blood pressure versus placebo.
In plain wordsIn obese adults, weight-loss drugs as a group, including liraglutide, did not meaningfully change blood pressure compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeBlood pressure, pooled weight-loss drugs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
without clinically meaningful changes in systolic/diastolic BP or cholesterol profile vs placebo (standardized mean difference <0.2); effects varied among drugs.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2930593308
09HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In obese adults, pooled FDA-approved weight-loss medications (including liraglutide) produced no clinically meaningful change in the cholesterol profile versus placebo.
In plain wordsIn obese adults, weight-loss drugs as a group, including liraglutide, did not meaningfully change cholesterol compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeCholesterol profile, pooled weight-loss drugs
Study
n: not reported in source
Comparator
Placebo
Outcome group
Lipids · Cardiovascular
Source sentences
Summary
without clinically meaningful changes in systolic/diastolic BP or cholesterol profile vs placebo (standardized mean difference <0.2); effects varied among drugs.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a systematic literature review through February 28, 2017 to identify randomized clinical trials of the effects of Food and Drug Administration-approved weight-loss medications (ie, orlistat, lorcaserin, naltrexone-bupropion, phentermine-topiramate, and liraglutide) administered to obese…
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-2930593309

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.